Skip to main content

Table 5 Procedure related characteristics according to pocket hematoma

From: Bleeding complications during cardiac electronic device implantation in patients receiving antithrombotic therapy: is there any value of local tranexamic acid?

Characteristics

PH positive group (n = 26)

PH negative group (n = 109)

P-value

INR at the day of implanta

2.1 (2.0–2.5)

2.0 (1.9–2.5)

0.122

Generator exchange and/or pocket revision, n (%)

3 (11.5)

11 (10.1)

1.0

New implantation, n (%)

19 (73.1)

82 (75.2)

1.0

Upgrade and/or lead revision, n (%)

4 (15.4)

16 (14.7)

1.0

Pacemaker, n (%)

1 (3.8)

23 (21.1)

0.045

ICD, n (%)

25 (96.2)

86 (78.9)

 

Number of leads implanted

 One, n (%)

2 (7.7)

24 (22.0)

0.165

 Two, n (%)

8 (30.8)

42 (38.5)

0.610

 Three, n (%)

13 (50.0)

32 (29.4)

0.076

 Submuscular pocket, n (%)

1 (3.8)

4 (3.7)

1.0

Venous route other than subclavian

 Axillary, n (%)

3 (11.5)

9 (8.3)

0.700

 Cephalic, n (%)

2 (7.7)

5 (4.6)

0.620

 Local tranexamic acid use

4 (15.4)

48 (44.0)

0.013

  1. DAPT dual antiplatelet therapy, ICD implantable cardioverter defibrillator, INR international normalized ratio, PH Pocket hematoma. a The median INR level of patients with warfarin continuation strategy